EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FANCI: from genome guardian to translational therapeutic target

Xiaoyue Zhang, Yang Zhang, Mengying Chen, Jinmei Wei, Yanling Li, Tao Dai, Junyu He, Chen Han, Yanhong Zhou

Frontiers in Oncology · 29.06.2026 · 16

DOI: 10.3389/fonc.2026.1885055 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 29.06.2026. Verfasst von Xiaoyue Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Chang…. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fanconi anemia complement group I (FANCI), a core component of the Fanconi anemia pathway, has emerged as a potential oncogenic factor across multiple cancer types. Located on chromosome 15q26.1, FANCI encodes a protein named FANCI that forms a stable heterodimer with FANCD2, playing a central role in the DNA damage response and repair. Beyond its involvement in DNA repair, FANCI participates in ribosome biogenesis, meiosis, and mRNA export, underscoring its essential role in maintaining genomic stability. Although FANCI deficiency has traditionally been associated with Fanconi anemia, recent studies have demonstrated that FANCI is overexpressed in various malignancies, where it promotes tumor progression and correlates with poor prognosis. The expression and activity of FANCI are tightly regulated at multiple levels, including transcriptional and post-transcriptional regulation by transcription factors and non-coding RNAs, as well as post-translational modifications such as phosphorylation mediated by PP2A and ATR, monoubiquitination catalyzed by the FANCL–UBE2T complex, and deubiquitination by USP1-UAF1. This review summarizes the functional mechanisms of FANCI across diverse physiological and pathological processes, highlighting its role as a crucial molecular bridge linking genomic stability maintenance to cancer development, and emphasizing its potential as a promising therapeutic target in cancer.

Schlagwörter

Stichwörter der Autor:innen

DNA damage repairFANCIinterstrand crosslink (ICL)malignant tumorstargeted therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
  • Cancer Research Institute, Basic School of Medicine, Central South University, Changsha, Hunan, China.
  • Medical Record Management and Information Statistics Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Nuclear Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
  • Urology Department, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Cancer Hospital, Changsha, Hunan, China.
  • Department of Clinical Laboratory, The Second People's Hospital of Hunan Province (Brain Hospital of Hunan Province), Changsha, Hunan, China.

Zitieren

APA

Zhang, X., Zhang, Y., Chen, M., Wei, J., Li, Y., Dai, T., He, J., Han, C., & Zhou, Y. (2026). FANCI: from genome guardian to translational therapeutic target. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1885055

Vancouver

Zhang X, Zhang Y, Chen M, Wei J, Li Y, Dai T, et al. FANCI: from genome guardian to translational therapeutic target. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1885055

BibTeX
@article{Zhang2026,
  author = {Zhang, Xiaoyue and Zhang, Yang and Chen, Mengying and Wei, Jinmei and Li, Yanling and Dai, Tao and He, Junyu and Han, Chen and Zhou, Yanhong},
  title = {FANCI: from genome guardian to translational therapeutic target},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1885055}
}
Kostenlos starten →